Current career situations of Chinese pharmacovigilance professionals working for pharmaceutical companies: an exploratory survey

Author:

Tang Yalan,Liu Yan,Liao Hongli,Yuan Yonghua,Jiang Qihua

Abstract

Abstract Background Pharmacovigilance in China has experienced rapid development in the past 30 years. The implementation of Good Pharmacovigilance Practice in China since the end of 2021 heralds a new era of pharmacovigilance affairs, which puts forward higher requirements for the quantity and quality of pharmacovigilance personnel. This study aimed to preliminarily explore the current career situations of pharmacovigilance professionals working in China for pharmaceutical companies. Methods A questionnaire was adapted from research in the USA and Europe with the help of several pharmacovigilance experts. Snowball sampling was used to conduct an exploratory survey to obtain the frequency of basic demographic information, work status, and career expectations of pharmacovigilance professionals working for pharmaceutical companies. Results The personnel engaged in pharmacovigilance work for pharmaceutical companies were mainly medical or pharmaceutical undergraduates within 3 years of graduation. Their work intensity and pressure were relatively high. The training provided by their universities and enterprises could not well meet their needs to improve their job competence. Although they were optimistic about pharmacovigilance and will not change their career, most of them were planning to change their employers. Conclusion There was a gap between the demand and supply of pharmacovigilance personnel. Relevant regulatory authorities and industry associations should guide higher education institutions to collaborate with pharmacovigilance specialists to strengthen pharmacovigilance education for medical or pharmaceutical students, on the basis of which pharmacovigilance certification courses and continuing education courses can be developed. Meanwhile, pharmaceutical enterprises should consider reasonably adjusting work intensity and income to avoid a high turnover rate.

Publisher

Springer Science and Business Media LLC

Subject

Health Policy

Reference25 articles.

1. World Health Organization. What is pharmacovigilance. 2022. https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance. Accessed 16 Dec 2022.

2. World Health Organization. Programme for international drug monitoring. 2022. https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance/health-professionals-info/pidm.

3. National Medical Products Administration. Measures for the reporting and monitoring of ADR. 2004. https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20040304010101771.html. Accessed 22 Aug 2022.

4. National Medical Products Administration. Measures for the reporting and monitoring of ADR. 2011. https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20110504162501325.html. Accessed 22 Aug 2022.

5. Zhang L, Wong LY, He Y, Wong IC. Pharmacovigilance in China: current situation, successes and challenges. Drug Saf. 2014;37(10):765–70.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3